Physician profile
Bikash Agarwal
NPI 1093700825
$2,157.96
in general payments reported to CMS, 2019-2025
22 companies · $250 in 2025
The $250 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $150 · 2020: $38.10 · 2021: $372 · 2022: $315 · 2023: $606 · 2024: $427 · 2025: $250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,282 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,282.44 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $412.93 | 2022-2024 | Watchman Flx, Watchman Access System |
| Inari Medical, INC. | $336.45 | 2021-2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Novo Nordisk INC | $193.53 | 2022-2023 | Rybelsus, Ozempic, Wegovy |
| Vifor Pharma, INC. | $147.92 | 2019-2021 | |
| Ani Pharmaceuticals, INC. | $125.00 | 2025 | Purified Cortrophin Gel |
| Horizon Therapeutics Plc | $125.00 | 2023 | Krystexxa |
| Esperion Therapeutics, INC. | $125.00 | 2021 | |
| Amgen INC. | $125.00 | 2024 | Krystexxa |
| Lilly USA, LLC | $125.00 | 2025 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $89.63 | 2019-2024 | Farxiga, Airsupra |
| Edwards Lifesciences Corporation | $66.95 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Abbvie INC. | $61.00 | 2022-2023 | Dalvance |
| Pfizer INC. | $41.68 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $41.05 | 2019 | |
| Sanofi-Aventis U.S. LLC | $37.31 | 2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $27.70 | 2019 | |
| Dexcom, INC. | $17.38 | 2023 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $16.17 | 2024 | Dificid |
| Mylan Specialty L.P. | $16.02 | 2019 | |
| Idorsia Pharmaceuticals US INC | $14.99 | 2023 | Quviviq |
| Ironwood Pharmaceuticals, INC | $11.46 | 2020 | |
| Sumitomo Pharma America, INC. | $0.79 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bikash Agarwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.